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Abstract 
Multiple  sclerosis  (MS)  is  the  most  com-
mon, non-traumatic cause of neurological dis-
ability in young adults. The aim of this study
was to investigate the influence of HLA class II
alleles DRB1* and DQB1* on susceptibility to
relapsing-remitting (RR) MS and response to
interferon (IFN) b-1a treatment. A prospective
observational study was conducted. Seventeen
patients with clinically definite RRMS, attend-
ing a tertiary referral center for multiple scle-
rosis  in  Israel  and  receiving  treatment  with
subcutaneous IFN b-1a, 22 mcg three times
weekly  were  recruited  between  December
1998 and February 2000 and observed for 12
months. HLA genotyping was performed and
clinical characteristics (relapse rate and dis-
ability progression) assessed at baseline and
after 12 months. HLA data for a healthy control
group were also used for comparison. HLA and
the success of treatment with IFN b-1a in this
group of RRMS patients were assessed. The
frequency of DRB1*03 was six times higher in
patients  treated  with  IFN  b-1a  than  in  the
healthy control group (n=100): 29% (5/17) ver-
sus  5%  (5/100),  respectively.  Additionally,
DQB1*03 and DQB1*02 were present in 82%
(14/17) and 41% (7/17) of RRMS patients, but
in only 33% (33/100) and 18% (18/100) of con-
trol patients, respectively. A better response to
IFN b-1a treatment was seen in patients carry-
ing these alleles than in patients without these
alleles.  Our  results  indicated  that  DRB1*03,
DQB1*03 and DQB1*02 alleles may contribute
to MS susceptibility and IFN b-1a responsive-
ness, and warrant further verification in a larg-
er population.
Introduction
Multiple  sclerosis  (MS)  is  the  most  com-
mon, non-traumatic cause of neurological dis-
ability in young adults. It is a chronic, inflam-
matory,  demyelinating,  immune-mediated,
neurodegenerative disease of the central nerv-
ous system (CNS) that occurs in genetically
susceptible patients and leads to progressive,
chronic, neurological disability. The course of
the disease is highly variable, with no reliable
prognostic  signs.  MS  can  be  classified  as
relapsing-remitting (RR), progressive relaps-
ing, secondary progressive, or chronic (or pri-
mary) progressive, based on the clinical mani-
festation of the disease.1-5
Although  the  etiology  of  MS  remains
unknown, genetic and immunological factors
have been implicated in its pathophysiology.
The  consensus  that  damage  to  the  nervous
system  is  the  result  of  an  immunological/
inflammatory process has been the foundation
on which current therapy for MS is based and
at which future drug development is aimed.6-8
Current therapy for RRMS is aimed towards
prevention of relapses, progression of the dis-
ease  (as  expressed  by  disability  accumula-
tion), and new lesion formation in the brain.
Corticosteroids are the mainstay of treatment
for  acute  exacerbations  and  are  thought  to
mediate their effects through the modulation
of  both  the  immune  system  and  systemic
endocrine function.9 It has been claimed that
immunosuppressive agents, such as azathio-
prine,  cyclophosphamide  and  cyclosporin-A,
reduce the number of relapses, but there is no
consensus on the efficacy of these drugs in
RRMS10 Other therapies that have been inves-
tigated  include  copolymer-1  and  interferon
(IFN), which are considered today to be dis-
ease-modifying drugs (DMDs) with beneficial
effects on relapse rates, disease progression,
new lesion formation and the burden of dis-
ease (as demonstrated by magnetic resonance
imaging [MRI]).11-14 
Several studies have indicated that relaps-
ing  forms  of  MS  may  be  associated  with  a
genetic  factor  in  the  HLA  class  II  region.
Specifically, patients carrying the HLA-DR-DQ
haplotypes  HLA-DRB1*1501,  -DRB5*0101,  -
DQA1*0102 or -DQB1*0602 were found to have
an  increased  risk  for  MS.  Indeed,  this  risk
increased  by  up  to  three  to  four  times  in
Western and European countries.15-29However,
the  influence  of  these  haplotypes  on  the
course of the disease in patients with relaps-
ing MS who are receiving IFN b-1a treatment
remains unknown.
As  well  as  HLA  haplotypes,  cytokines  also
play a crucial role in the pathogenesis of MS.
They have specific effects on cell communica-
tion and behavior, and on cell-to-cell interac-
tion.7,30
Pro-inflammatory cytokines, such as inter-
leukin  (IL)-2,  IL-12,  tumour  necrosis  factor
(TNF) a and IFN g, are produced by Th1 cells
and  activate  immune  cells  to  enhance  the
expression  of  adhesion  molecules  and
chemokines. They also render the blood-brain
barrier (BBB) more permeable to soluble and
cellular  components  of  the  immune  system,
thereby facilitating the development of inflam-
matory lesions in the CNS.7 Anti-inflammatory
cytokines, such as IL-4, -6, -10, -13 and trans-
forming growth factor (TGF) b, are produced
by Th2 cells and can down regulate the inflam-
matory response.7,30
Cell adhesion molecules (CAMs) also play a
key role in the pathogenesis of the inflamma-
tory response in MS. Activated T cells adhere to
the microvasculature using CAMs before pass-
ing  through  the  endothelial  barrier.  Once
inside the CNS, T cells are activated and an
inflammatory response is initiated by cytokine
secretion. Adhesion molecules are up regulat-
ed, T cells proliferate and additional effectors
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[Neurology International 2011; 3:e5] [page 17]cells are recruited, leading to the destruction
of myelin and oligodendrocytes. Up-regulation
of adhesion molecules, in particular vascular
cell  adhesion  molecule-1  and  intercellular
adhesion  molecule-1  (ICAM-1),  has  been
demonstrated in the brain of patients with MS,
especially  in  the  proximity  of  inflammatory
lesions.31,32 Increased levels of soluble ICAM-1
have also been found in the blood of clinically
active  patients  with  relapse  or  MRI  activity,
and  were  found  to  correlate  with  increased
TNF-a,  cerebrospinal  fluid  pleocytosis  and
BBB damage.33-35
The aims of this study were two-fold. The
first objective was to compare the frequency of
HLA  class  II  alleles  DRB1*  and  DQB1*  in
RRMS patients, attending a centre in Israel,
with that in healthy individuals. The second
objective was to assess the influence of these
HLA  alleles  on  responsiveness  to  IFN  b-1a
(number of relapses and disability, as assessed
by  the  Expanded  Disability  Status  Scale
[EDSS]  score)  in  patients  with  RRMS.  The
effects of treatment on serum expression of
various pro-inflammatory and anti-inflamma-
tory cytokines, and adhesion molecules (TNF-
a, IFN-g, ICAM-1, IL-4, IL-10 and TGF b) were
also assessed in these patients.
Materials and Methods
Patients
This  was  an  observational  open  study
designed  for  one  year  of  follow-up.
Consecutive  patients  with  RRMS  receiving
treatment with subcutaneous IFN b-1a, 22 mcg
three times weekly at the centre were recruit-
ed between December 1998 and February 2000.
All patients enrolled in the study had clinically
definite  MS,  according  to  Poser’s  criteria,36
specifically RRMS. The patients were disease-
modifying-drug-naive  patients.  All  patients
gave informed consent prior to their inclusion
in the study by signing an informed consent
form and the study was approved by the Local
Ethics  Committee  at  Assaf  Harofeh  Medical
Center, and therefore the study was performed
in accordance with the ethical standards laid
down in the 1964 Declaration of Helsinki.
HLA data for a control group were also used
for comparison. This control group comprised
healthy individuals from the general popula-
tion with information stored on a central data-
base held by the Tissue Typing Unit at Rabin
Medical Center, affiliated to the University of
Tel Aviv, Israel.
Assessments
Clinical characteristics (relapse rate, EDSS
score) were assessed at baseline and after 12
months of treatment. Response to treatment
from baseline to 12 months was rated as ‘high’
(no relapses; with improvement of 1 point in
EDSS),  medium  (≥50%  reduction  in  relapse
rate; improvement of 1/2 point or no change in
EDSS) or low (<50% reduction in relapse rate;
deterioration in EDSS). HLA genotyping was
conducted at the start of the study. Serum bio-
marker expression (ICAM-I, TNF-a, TGF b, IL-
10, IFN-g) was measured at baseline and at 3-
monthly  intervals  throughout  the  12-month
study. 
HLA genotyping
HLA  genotyping  (class  ІІ,  DRB1*/DQB1*
alleles)  was  performed  on  blood  samples  by
low-resolution  analysis  using  polymerase
chain  reaction  (PCR)  amplification  and
sequence-specific  primers.  Tissue  typing  for
HLA  was  performed  using  the  National
Institute  of  Health  microlymphocytotoxicity
technique. DNA-based low-medium resolution
analysis for DRB1* and DQB1* alleles was per-
formed  using  PCR  amplification  with
sequence-specific  primers.  For  those  alleles
found to have significantly increased frequen-
cy,  high-resolution  analysis  was  done  by
means of PCR sequence-specific oligotyping. 
Biomarker expression
Blood  serum  was  collected  at  3-monthly
intervals  and  stored  at  -70ºC.  Levels  of
cytokines  were  measured  by  using  Enzyme
Linked  Immunosorbent  Assay  (ELISA)
(Commercial kits T-cell Diagnostics).
Treatment
Patients  were  treated  on  an  out-patient
basis. Subcutaneous IFN b-1a (Rebif®, Merck
Serono  International  S.A.,  Geneva,
Switzerland)  was  administered  three  times
weekly at a dose of 22 mcg (6 MIU) for 12
months.
Statistical analysis
The statistical evaluations were performed
by Medistat, a company conducting statistical
reviews  for  medical  purposes.  The  company
sponsoring the research did not conduct any
statistical evaluations. A paired t-test and non-
parametric sign-rank tests were used to test
for differences between EDSS scores and the
relapse  rate  before  and  after  12  months  of
treatment with IFN b-1a. A 2-sample t-test and
non-parametric test were applied for testing
differences between the study groups for quan-
titative  parameters.  Spearman’s  correlation
was applied for testing the correlation between
the study parameters examined.
All tests applied were 2-tailed, and P values
of 5% or less were considered statistically sig-
nificant.  Data  were  analyzed  using  the  SAS
software (SAS Institute, Cary, NC, USA). 
Results
Patient characteristics
A total of 17 patients with definite RRMS
were  included  in  the  RRMS  group  and  data
from  100  healthy  subjects  was  used  for  the
control  group.  Patient  demographics  for  the
RRMS group and the healthy control group are
presented in Table 1. The majority of patients
in  the  RRMS  group  originated  from  Israel
(n=10),  two  were  from  Iran,  and  one  each
from Belgium, Georgia, Romania, Russia and
Ukraine.  Patients  were  either  of  Ashkenazi
(n=9) or Sephardi (n=8) ethnicity. 
Treatment response
Clinical follow-up after 12 months of IFN b-
1a treatment demonstrated a statistically sig-
nificant  decrease  in  the  mean  number  of
relapses compared with the annualised rate 2
years  pre-baseline  0.7  (1.1)  vs 1.29  (1.7  );
Article
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Table 1. Patient demographics.
Treatment Group
IFN b-1a,  Healthy
22 mcg sc tiw Controls
(N=17) (N=100)
Age, mean (SE), years  33(2.7) 37 (2.6)
Gender
Female 11 63 (63)
Male 6 37 (37)
Duration of disease, mean (SE), y 11.6 (1.8) NA
Number of relapses annualized prior  1.29 (1.7) NA
to treatment, mean (SE)
Number of relapses after 12 months  0.7 (1.1)* NA
of treatment, mean (SE)
EDSS prior to treatment, mean (SE) 2.6 (0.2) NA
EDSS after 12 months of treatment,  2.3 (0.3)** NA
mean (SE)
EDSS, Expanded Disability Status Scale; sc, subcutaneously; SE, standard error; tiw, three times weekly; NA, not applicable.  *P<0.001 vs con-
trol. **P<0.075 vs control.P<0.001  (Figure  1a).  In  IFN  b-1a-treated
patients,  EDSS  scores  improved  in  nine
patients, remained stable in five and deterio-
rated  in  three;  mean  (SE)  EDSS  scores
decreased from 2.6 (0.2) pre-treatment to 2.3
(0.3) post-treatment (P<0.075) (Figure 1b).
HLA genotyping
HLA  class  II  genotyping  demonstrated  that
the  frequency  of  DRB1*03,  DQB1*03  and
DQB1*02 alleles was significantly higher in the
patients with RRMS than in the control group
(P<0.05) (Figure 2). Patients with these HLA
alleles demonstrated a better responsiveness to
IFN b-1a treatment than those without the alle-
les, according to both the number of relapses,
and their levels of disability (Figure 3). 
Biomarker expression
Biomarker  expression  at  baseline  and
changes after treatment are shown in Figure 4.
TGF b expression showed the greatest effect,
with the majority of patients (12/17, 71%) hav-
ing levels below normal before treatment and
the majority of patients (13/17, 76%) showing
an increase in TGF b levels after treatment. 
Discussion
Understanding  of  the  etiology  and  patho-
genesis of MS has changed over time. Current
progress in molecular genetics has contributed
to the hypothesis that MS should be consid-
ered as a genetically determined disorder.1,2,6
Indeed, much effort has been made to identify
the genetic factors involved in MS. To date,
only one factor of confirmed importance has
been identified: the HLA class II region on the
short arm of chromosome 6.15-29 Studies have
reported that carrying the HLA class II DR-DQ
haplotypes:  DR15,  DQ6  and  DW2,  known  in
genomic  terminology  as  HLA-DRBI*1501,
DRB5*0101, DQA1*0102, DQB1*0602, increas-
es the risk for MS by three to four times in
Western and European populations.15-29
The prevalence of the HLA-DW2 genotype is
high in Europe and North America, but it can
be detected in most ethnic groups. Although its
frequency is identical in both patients with MS
and healthy individuals, it confers a four-fold
increase in the risk for MS. A possible applica-
tion of the HLA association in MS might be
that the DW2 haplotype could serve as a prog-
nostic marker; other studies suggest that those
individuals  with  the  DW2/DR2  haplotypes
might have a worse prognosis than individuals
who do not carry these haplotypes.37,38
Other HLA haplotypes have also been associ-
ated with MS, including DR3 and DQ2, but to a
lesser degree than DW2.26,39,40The DR3 associ-
ation is with the DR17, DQ2 haplotype, pre-
Article
[Neurology International 2011; 3:e5] [page 19]
Figure  1.  (A)
Number of relapses
and  (B)  expanded
disability  status
scale (EDSS) scores
before and after 12
months  of  treat-
ment with interfer-
on beta-1a, 22 mcg











and  healthy  indi-
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relapse rate.sented  as  HLA-DRB1*0301,  DRB3*0101,
DQA1*0501,  DQB1*0201.41 In  some  studies
comparing  Brazilian  MS  patients  of  African
origin  with  ethnically  matched  controls
[17m23],  an  increased  frequency  of  DQ6
(DQA1*0201, DQB1*0602) in the absence of
DR15  was  observed.  This  observation  may
indicate that the DQ molecule rather than the
DR molecule is functionally responsible for the
disease-predisposing  association  in  MS.  A
Sardinian study found DR4 to be increased in
patients with MS compared with control indi-
viduals.42
In our study, we examined the frequency of
HLA  class  II  alleles  DRB1*  and  DQB1*  and
found  a  higher  frequency  of  DRB1*03,
DQB1*03 and DQB1*02 alleles in patients with
RRMS  compared  with  the  healthy  control
group. Furthermore, patients with RRMS car-
rying these alleles showed a better response to
IFN  b-1a  treatment  than  those  who  did  not
carry these alleles, as was shown. This sug-
gests  that  the  DRB1*03,  DQB1*03  and
DQB1*02 alleles may be involved in both dis-
ease  susceptibility  and  IFN  b-1a  response.
Although our findings from this small cohort
warrant further investigation in a larger popu-
lation,  they  indicate  that  the  DRB1*03,
DQB1*03 and DQB1*02 alleles may have utili-
ty as pharmacogenomic markers in RRMS. 
As  MS  is  characterized  by  inflammatory
mechanisms, genes encoding cytokines, such
as TNF-a and IFN-g, are important candidates
for genetic markers in MS, particularly as they
reside  between  the  HLA  class  I  and  II
regions.43,44 TNF-a and TNF b are believed to
contribute to tissue injury in MS by enhancing
the local inflammatory process via recruitment
and activation of other inflammatory cells con-
tributing to myelin damage.45 The production
of IL-10 by activated macrophages and T cells
exerts  an  anti-inflammatory  effect  by  down-
regulating the production of IFN-g and major
histocompatibility  complex  (MHC)  class  II
expression on monocytes.46 In active and sta-
ble  MS,  serum  IL-10  levels  may  be  low.47,48
Levels of IL-4 and TGF b can be decreased or
increased in patients with MS; high levels are
seen in short-term disease with minor disabil-
ity and are more common in RRMS than in sec-
ondary  progressive  MS.49 TGF  b is  a  potent
anti-inflammatory cytokine, which is produced
by CD8+ and CD45 RA+ cells. It suppresses the
expression of pro-inflammatory cytokines and
counteracts IFN-g- and TNF-a-mediated aber-
rant MHC class II expression.49
In our study, we monitored the effect of IFN
b-1a treatment on the levels of many of the
key molecules implicated in MS (ICAM-I, TNF-
a, TGF b, IL-10, IFN-g). Of the cytokines we
measured, TGF b and IFN-g showed the most
interesting patterns. Most of the patients with
RRMS (71%) had subnormal levels of TGF b at
baseline. In the 17 patients we studied, treat-
ment resulted in an increase in TGF b levels
in  most  cases  (76%).  An  increase  in  this
potent  anti-inflammatory  cytokine  would  be
expected  to  counteract  the  production  of
inflammatory  cytokines  such  as  IFN-g and
aberrant  MHC  class  II  expression.49 These
effects  should  reduce  disease  activity  and,
indeed, a significant improvement in relapse
rates and EDSS scores was seen in this popu-
lation by the end of the study. The complexity
and heterogeneity of MS, leads to difficulties
in the selection of an appropriate DMD, since
the effects of these drugs may differ according
to the genetic susceptibility of the patient. The
possibility of genetic screening before the ini-
tiation of a specific treatment may permit the
tailoring of appropriate therapy to the individ-
ual patient, so improving the prognosis. The
results, which demonstrated a high beneficial
effect of the treatment with IFN b 1a among
the  patients  carrying  these  certain  alleles,
should be judged cautiously, since the number
of the patients was small, and more extensive
studies,  both  prospective  and  retrospective,
with a larger number of patients and different
disease-modifying drugs, are needed to verify
this hypothesis.
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